SCHEMBL4492018

SCHEMBL4492018

Cc1[nH]c(C)c(-c2ccc(-c3cccc(C(F)(F)F)c3)nc2)c(=O)c1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.51
SLC11A2 P49281 1/20 0.43
KDM1A O60341 3/20 0.42
MAOB P27338 2/20 0.42
MAPT P10636 1/20 0.42
XDH P47989 1/20 0.42
DHODH Q02127 1/20 0.42
IDO1 P14902 1/20 0.41
IKBKB O14920 1/20 0.40
SCN2A Q99250 2/20 0.40
PIN1 Q13526 1/20 0.40
CDC7 O00311 1/20 0.39
GRIN1 Q05586 3/20 0.39
GRIN2B Q13224 3/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 2/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4565033 0.88 SLC2A1 (0.43) SLC2A1SLC11A2KDM1AMAOBKDM4E
SCHEMBL4493390 0.87 SLC2A1 (0.66) SLC2A1SLC11A2KDM1AMAOBXDH
SCHEMBL4490539 0.85 KDM1A (0.41) SLC2A1KDM1AMAOBMAPTIDO1
SCHEMBL4471107 0.84 XDH (0.45) SLC2A1XDHDHODHGRIN1GRIN2B
SCHEMBL4472769 0.84 KDM1A (0.45) SLC2A1KDM1AMEN1KMT2A
SCHEMBL4491220 0.84 SLC2A1 (0.43) SLC2A1KDM1A
SCHEMBL4486314 0.83 SLC2A1 (0.43) SLC2A1KDM1AALDH1A1PKM
SCHEMBL4485644 0.83 FEN1 (0.44) SLC2A1
SCHEMBL13754687 0.82 HPGDS (0.43) SLC2A1MAPTDHODHKDM4EHSD17B10
SCHEMBL4486775 0.82 SLC2A1 (0.46) SLC2A1SLC11A2KDM1AMAOBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US claimed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US claimed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
EP-1858876-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2007-11-28 EP disclosed
WO-2006094799-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287461-A1 Pyridinone Derivatives Against Malaria G6PD, PNPO, PLPBP SLC2A1 2278/4885SLC11A2 1320/4885KDM1A 1359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.